Immune checkpoint modulators

Atezolizumab (anti-PD-L1) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Atezolizumab (anti-PD-L1) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Atezolizumab (anti-PD-L1) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Atezolizumab (anti-PD-L1) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.Purity&gt95% (SDS-PAGE&ampSEC)Endotoxin Level&lt 1.0EU/mg

Dostarlimab (anti-PD-1) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab (anti-PD-1) binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM,

Dostarlimab (anti-PD-1) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab (anti-PD-1) binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM,

Dostarlimab (anti-PD-1) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab (anti-PD-1) binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM,

Dostarlimab (anti-PD-1) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab (anti-PD-1) binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM,

feladilimab

feladilimab

inotuzumab ozogamicin

inotuzumab ozogamicin